Shop by goal

Popular compounds

GHK-Cu

GLP1-RC-RT

Research resources

Certificates of Analysis

Tirzepatide: Metabolic Research research guide

In short: Tirzepatide is a dual GIP / GLP-1 receptor agonist characterised in published research, with imbalanced agonism favouring GIPR. GLP1-RC-TZ is the New-U catalogue identifier for the analytically verified laboratory research material supplied here. It is studied in preclinical (cell and animal) research and is supplied strictly for laboratory use, not for human or clinical use.

Not medical advice. Tirzepatide is a research compound. This guide does not provide dosing, diagnosis, therapy recommendations, or claims about effects in humans.

Tirzepatide at a glance

Compound type

Research peptide

Research category

Metabolic Research

Also known as

GIP/GLP-1 Dual Agonist, Dual Incretin Agonist, Twincretin

Molecular weight

4,813.53 Da

Research-grade purity

>99% HPLC

Evidence context

Preclinical / research use only

Regulatory status

Not an approved medicine. Supplied as a research compound

Last reviewed

14 August 2026

What to know first

Useful reference compound for receptor pharmacology and metabolic disease models in compliant research settings.

Receptor pharmacology: dual GIPR / GLP-1R agonist activity characterised in published in-vitro studies

Imbalanced agonism reported — full GIPR potency with GLP-1R signalling biased toward cAMP over β-arrestin recruitment

Aib2 and Aib13 substitutions investigated for DPP-IV and protease resistance

C20 fatty-diacid modification reported to give 99% albumin binding; apparent elimination half-life reported at ~5 days

Details and limits sit in the sections below. Research use only.

What Tirzepatide is

Tirzepatide combines GLP-1 and GIP activity in one molecule; papers highlight dual incretin mechanisms and metabolic endpoints in controlled studies.

One-paragraph overview from our research datasheet. Still scientific, but faster to read than the full mechanism list below.

Tirzepatide is a dual GIP / GLP-1 receptor agonist characterised in published research, with imbalanced agonism favouring GIPR. GLP1-RC-TZ is the New-U catalogue identifier for the analytically verified laboratory research material supplied here.

Quick takeaways

Useful reference compound for receptor pharmacology and metabolic disease models in compliant research settings.

Research contexts

Peer-reviewed papers discuss Tirzepatide in specific lab settings. The points below reflect research questions, not health claims.

Research vs. personal use: Literature describes experiments in cells and animals. That is distinct from real-world use. Our products are for laboratory research only.

Typical study contexts

Clinical development literature discusses dual incretin biology; again, that is distinct from non-clinical research SKUs.

Animal models frequently measure body composition, glucose curves, and hormone levels as mechanistic readouts.

Incretin pathways, food intake and glucose handling in rodent models.

Some drug-class molecules have clinical trials. Those are distinct from catalogue research use.

Receptor pharmacology: dual GIPR / GLP-1R agonist activity characterised in published in-vitro studies.

Imbalanced agonism reported — full GIPR potency with GLP-1R signalling biased toward cAMP over β-arrestin recruitment.

Aib2 and Aib13 substitutions investigated for DPP-IV and protease resistance.

C20 fatty-diacid modification reported to give 99% albumin binding; apparent elimination half-life reported at ~5 days.

Why Metabolic Research research matters

Metabolic-research peptides are studied for incretin-receptor pharmacology and energy-balance endpoints. The literature reports mechanisms and study endpoints, not guidance for any use.

Mechanisms (technical review)

Our datasheet lists mechanistic themes from preclinical work. These are research endpoints, not health claims.

Receptor pharmacology: dual GIPR / GLP-1R agonist activity characterised in published in-vitro studies

Imbalanced agonism reported — full GIPR potency with GLP-1R signalling biased toward cAMP over β-arrestin recruitment

Aib2 and Aib13 substitutions investigated for DPP-IV and protease resistance

C20 fatty-diacid modification reported to give 99% albumin binding; apparent elimination half-life reported at ~5 days

SURMOUNT-1 RCT (NEJM 2022, PMID 35658024), 15 mg arm: investigators reported −20.9% mean change from baseline in body weight at week 72

SURPASS programme: investigators reported HbA1c reductions of up to 2.58% as a protocol-defined endpoint

Lab handling & preparation

Storage: Lyophilised powder: store in freezer (−20 °C). Reconstituted: refrigerate 1–6 °C, away from sunlight. Use within the validated stability window for the specific batch and formulation.. See the storage guide.

Published pharmacokinetic context: Published pharmacokinetic research reports an apparent elimination half-life of approximately 5 days (mean 116.7 h), Tmax of 8–72 h, volume of distribution ~10.3 L, 99% albumin binding and subcutaneous bioavailability of ~80%. Metabolism is reported as proteolytic cleavage, C20 diacid β-oxidation and amide hydrolysis, with metabolites eliminated ~66% renally and ~33% faecally and no CYP-mediated interactions.

Purity check: Use the COA reading guide and the published Tirzepatide Certificate of Analysis.

Common Questions People Are Asking

What is Tirzepatide in scientific research?

Tirzepatide (LY3298176) is a 39-amino-acid synthetic peptide characterised in receptor-pharmacology studies as a dual GIP / GLP-1 receptor agonist with imbalanced agonism. It is approved as a medicine in some jurisdictions under other manufacturers' brand names; the material supplied here is not that finished pharmaceutical.

What is GLP1-RC-TZ?

GLP1-RC-TZ is New-U's catalogue identifier for the laboratory research material offered through this research profile. It is not a medicine, a treatment, a generic pharmaceutical or a therapeutic product, it is not equivalent to any clinical or commercial product, and it is not offered for human or veterinary use.

Which receptor systems are examined in Tirzepatide research?

Published in-vitro pharmacology characterises two receptors: GIPR, where agonist potency is reported as comparable to native GIP, and GLP-1R, where signalling is reported as biased toward cAMP generation over β-arrestin recruitment. Structural work additionally investigates the C20 fatty-diacid albumin-binding modification and the Aib2/Aib13 substitutions for altered proteolytic stability.

What analytical testing accompanies GLP1-RC-TZ?

Each released GLP1-RC-TZ batch is tested by an independent analytical laboratory for purity by RP-HPLC area normalisation and for identity by mass spectrometry, and the result is published as a batch-linked Certificate of Analysis recording the laboratory, report number, measured purity and test date. Batch analysis reports identity and purity for the sample tested. It does not establish sterility, endotoxin or heavy-metal status, pharmaceutical equivalence, or any clinical property.

Where can I view the current batch COA for GLP1-RC-TZ?

The current batch certificate — laboratory, report number, measured purity and test date — is published at /coa/tirzepatide, together with the testing history for the compound.

What does >99% HPLC purity mean?

It is a purity figure obtained by reversed-phase high-performance liquid chromatography using area normalisation: the target peak accounts for more than 99% of the total integrated peak area in the chromatogram for the tested sample. It is a statement about chemical purity of that sample only, and says nothing about sterility, endotoxin content, pharmaceutical equivalence or any clinical property.

What clinical trials are referenced on this page?

Three external studies of the reference medicine: SURMOUNT-1 (Jastreboff et al., NEJM 2022; PMID 35658024), SURMOUNT-5 (Aronne et al., NEJM 2025; PMID 40353578) and SURPASS-CVOT (NEJM 2025; DOI 10.1056/NEJMoa2505928), alongside the receptor-pharmacology characterisation in JCI Insight (2020). Each reported result on this page is attributed to its study, arm and timepoint.

How is published clinical research distinguished from New-U batch testing?

They are separate bodies of evidence. Published clinical research is external work on the approved finished pharmaceutical, conducted under those studies' own protocols; it establishes nothing about the material supplied here. New-U batch testing is analytical work on the GLP1-RC-TZ lot itself — RP-HPLC purity and mass-spectrometry identity — and it establishes nothing clinical. A certificate of analysis combined with an external clinical paper does not amount to clinical validation of GLP1-RC-TZ.

Is GLP1-RC-TZ the same as an approved branded medicine?

No. Approved branded tirzepatide products are prescription, sterile finished pharmaceuticals manufactured under cGMP by their marketing authorisation holder. GLP1-RC-TZ is unapproved laboratory research material supplied as a lyophilised powder. It is not equivalent to, a generic of, or a substitute for any approved product.

Why is Tirzepatide described as imbalanced in the literature?

Because the two receptor arms are not matched: published pharmacology reports full agonist potency at GIPR comparable to native GIP, but biased signalling at GLP-1R that favours cAMP generation over β-arrestin recruitment. The literature investigates that asymmetry in relation to receptor desensitisation over prolonged exposure.

How does Tirzepatide research differ from Retatrutide and Semaglutide research?

By receptor coverage as characterised in the literature: semaglutide research describes GLP-1R agonism, tirzepatide research describes GIPR/GLP-1R agonism, and retatrutide research investigates GLP-1R/GIPR/GCGR agonism. Only SURMOUNT-5 was designed as a head-to-head comparison (tirzepatide vs semaglutide); results drawn from separate programmes are not head-to-head comparisons.

What form is GLP1-RC-TZ supplied in?

GLP1-RC-TZ is supplied as a lyophilised powder in sealed vials, in sealed 10-vial research packs across the listed strengths, with a batch-linked Certificate of Analysis.

How should laboratory research material be stored?

Store the lyophilised powder in a freezer at −20 °C. If a laboratory protocol requires the material in solution, hold the resulting solution refrigerated at 1–6 °C, protected from light, and avoid repeated freeze–thaw cycles, which can degrade the fatty-acid modification. Storage conditions are laboratory handling information only.

Is this page medical advice? Can I use Tirzepatide for my health?

No, and no. This article is educational only. We do not provide dosing, medical recommendations, or health claims. Our products are sold strictly for laboratory research, not for personal use of any kind.

Where do I find Tirzepatide specs, purity certificates and pricing?

Open the shop listing via “View product details.” There you will see batch specs, the Certificate of Analysis (COA), concentration, purity grade, and available SKUs with current pricing.

Related peptide guides

Other compounds researchers often read about alongside Tirzepatide.

Retatrutide - companion guide

Semaglutide - companion guide

Cagrilintide - companion guide

Eloralintide - companion guide

Scientific sources & further reading

Primary literature and registries for Tirzepatide, plus mainstream coverage of the peptide category. Research use only - not medical advice.

Databases & literature:

PubMed: peer-reviewed literature on Tirzepatide

ClinicalTrials.gov: registered studies on Tirzepatide

Tirzepatide: Wikipedia (search)

Peptides in the news:

WebMD: consumer health reference

BBC News: Health

CNN Health: “Peptides: what to know about the wellness trend”

Sky News: “Can peptides make America healthy again?”

Sky News: “Inside the exploding US peptides craze” (video)

Sky News Australia: “Black market peptide trade explodes as influencers fuel uptick in use”

Sky News Australia: “Backyard peptide boom sparks alarm” (video)

Sky News Australia: “Oprah reveals struggle with shame of weight-loss drugs”

Ready to order? View full product specs

Access concentration, batch info, variants, and current pricing on our shop.

Also known as: GIP/GLP-1 Dual Agonist, Dual Incretin Agonist, Twincretin

PRECISION. PURITY. PERFORMANCE.

Research peptides at >99% HPLC-verified purity, third-party tested by Janoshik Analytical & Freedom Diagnostics, with Certificates of Analysis published per released batch. Supplied strictly for laboratory research use.

Shop

All research compounds

Price list

Where to buy peptides

Research